STING1 and neoplasm: Based on promising pre-clinical observations of host STING pathway involvement in endogenous local and systemic antitumor immune responses, the administration of STING agonists has been explored as a therapeutic strategy for the exogenous activation of pDCs resulting in prolonged survival and reduced tumor growth [242, 282, 284–286].